ASX:CSL
ASX:CSLBiotechs

A Closer Look at CSL (ASX:CSL) Valuation Following Capital Markets Day and Guidance Downgrade

CSL (ASX:CSL) is in the spotlight as it hosts its Capital Markets Day event, presenting strategic priorities and growth initiatives for investors. The timing comes after a recent guidance downgrade and market volatility. See our latest analysis for CSL. Despite promising long-term trends in core plasma and vaccine markets, CSL’s share price return has slid sharply this year, with a 30-day drop of 14.3% and a year-to-date fall of 37.3%. After briefly rallying on hopes for operational...
ASX:WDS
ASX:WDSOil and Gas

Does Woodside Offer Value After LNG Investment Announcement and a 14.5% Rise in 2025?

Curious if Woodside Energy Group stock is a genuine bargain or just riding the waves? Let’s dig into what’s really behind its current price tag. Shares have moved up 4.1% over the past week and are now up 14.5% for the year, pointing to renewed optimism and perhaps changing views on future prospects. The stock has drawn attention lately after the company announced additional investment in its LNG projects, which industry watchers believe could drive long-term growth. Broader energy market...
ASX:SHL
ASX:SHLHealthcare

Sonic Healthcare (ASX:SHL): Evaluating Value After This Year’s Share Price Drop and Steady Revenue Growth

Sonic Healthcare (ASX:SHL) has caught attention lately, as its stock price dropped 24% since January. While the market has sold off, the company’s revenue continues to edge higher. Its shares now trade below their five-year average price-to-sales ratio. See our latest analysis for Sonic Healthcare. After a tough year, Sonic Healthcare’s share price has fallen 24.4% year-to-date. This reflects a shift in sentiment as investors weigh its steady revenue growth against changing market risks...
ASX:NSR
ASX:NSRSpecialized REITs

Does National Storage REIT’s Expansion Signal Real Value After a 6% Share Price Dip?

Curious whether National Storage REIT might be a hidden gem or an overhyped pick? Let's take a closer look at what could be shaping its true value. The stock has seen a dip of 6.2% over the last week and is down 4.8% over the past year, although its five-year return still stands strong at 56.3%. Recent news highlights the company's ongoing expansion efforts with strategic property acquisitions and enhanced sustainability initiatives. Both of these have stirred fresh interest from investors...
ASX:CLV
ASX:CLVChemicals

Clover And 2 Other ASX Penny Stocks To Watch

With the Reserve Bank's recent decision to hold interest rates steady and earnings season concluded, Australian shares are experiencing a period of uncertainty, with the ASX 200 attempting to rebound from a six-week low. In this context, penny stocks—though an older term—remain relevant for investors seeking opportunities in smaller or emerging companies that may offer growth potential. By focusing on those with solid financial health and clear growth prospects, investors can uncover...
ASX:SUL
ASX:SULSpecialty Retail

Super Retail Group (ASX:SUL): Valuation Insights Following New CEO Appointment and Leadership Transition

Super Retail Group (ASX:SUL) has named Paul Bradshaw as its next CEO, effective November 1, 2025, following the recent departure of its previous chief executive due to governance issues. Bradshaw’s three decades of retail leadership could signal a stable transition for investors. See our latest analysis for Super Retail Group. Super Retail Group’s leadership updates come on the heels of a solid long-term run for investors. The total shareholder return over the past year stands at 17%, and an...
ASX:TLX
ASX:TLXBiotechs

Telix Pharmaceuticals (ASX:TLX): Examining Valuation After SEC Subpoena and Ongoing Legal Probes

Telix Pharmaceuticals (ASX:TLX) has disclosed that it received a subpoena from the U.S. Securities and Exchange Commission regarding statements about its prostate cancer therapeutics. This has prompted several law firms to investigate possible securities violations. See our latest analysis for Telix Pharmaceuticals. The pressure from regulatory scrutiny and legal investigations has weighed on Telix Pharmaceuticals’ momentum, with the share price dropping 33.9% year-to-date and the 1-year...
ASX:ING
ASX:INGFood

Inghams Group (ASX:ING) Valuation Perspective Following Share Price Slide and Turnaround Moves

Inghams Group (ASX:ING) is navigating a rough patch, with its share price falling sharply as the company grapples with declining poultry volumes, revenue, and profit. The drop has prompted swift action on multiple operational fronts. See our latest analysis for Inghams Group. Inghams Group’s share price has lost considerable ground this year, sliding to A$2.39 and notching a 90-day price return of -29.5% as the company faces operational headwinds. While short-term momentum is fading, the...
ASX:ALK
ASX:ALKMetals and Mining

Alkane Resources (ASX:ALK): Evaluating Valuation After Strong 12-Month Share Price Rally

Alkane Resources (ASX:ALK) has delivered a sharp turnaround over the past year, catching the attention of market watchers. Shares have climbed nearly 90% in 12 months, reflecting strong momentum and shifting investor sentiment. See our latest analysis for Alkane Resources. Momentum around Alkane Resources has intensified lately, with the company’s latest 90-day share price return of nearly 33% highlighting renewed optimism following last year's breakout. While its one-year total shareholder...
ASX:NST
ASX:NSTMetals and Mining

Northern Star Resources (ASX:NST): Evaluating Valuation After Quarterly Results and Forward Guidance Reaffirmation

Northern Star Resources (ASX:NST) released its first quarter results, selling 381,000 ounces of gold at an all-in sustaining cost of A$2,522 per ounce. The company also reaffirmed its guidance for fiscal year 2026. See our latest analysis for Northern Star Resources. After a year of sustained momentum, Northern Star Resources has seen its share price climb 54.8% year-to-date, with a three-year total shareholder return of 175.6% highlighting steady outperformance. This recent rally suggests...
ASX:CIA
ASX:CIAMetals and Mining

Champion Iron (ASX:CIA) Valuation in Focus Following Strong Q2 Earnings and Dividend Announcement

Champion Iron (ASX:CIA) just announced its second quarter earnings, revealing sharp growth in sales and net income from a year earlier, and declared a semi-annual dividend. This news has caught the attention of many investors. See our latest analysis for Champion Iron. Positive momentum is clearly building for Champion Iron, with the latest results and dividend likely sparking increased interest from investors. After sliding earlier in the year, the stock’s 14.7% jump over the past week and...